From James H. Essell, MD, Transplant Specialist and Co-Director of Research at OHC
May 11, 2017
A new Patient Survival Report by the U.S. Department of Health and Human Services’ Health Resources and Services Administration reveals OHC/ Jewish Hospital – Mercy Health Blood Cancer Center are leading in survival rates.
The report shows that allogeneic patients (recipients of bone marrow transplants using cells from related and unrelated donors) of the Blood Cancer Center have the highest survival rate for one year.
“What’s most important about these results is that physicians can refer their patients locally. The patients can stay here, where they live, and receive the highest level of care without leaving town,” said James H. Essell, MD, OHC hematologist-oncologist, Medical Director of the Blood Cancer Center.
Allogeneic stem cell transplantation is a treatment that uses healthy donor stem cells to replace a patient’s marrow and blood cells. The transplantation process requires high doses of chemotherapy and/or radiation to destroy cancer cells living in the bone marrow and replace the diseased cells with a healthy bone marrow and immune system. It is used to cure acute myelogenous leukemia, acute lymphocytic leukemia, myelodysplasia and other forms of blood cancers. The chemotherapy and radiation leave the patient without an immune system or the ability to make blood cells until the new marrow engrafts. A highly skilled team such as OHC and The Jewish Hospital Blood Cancer Center is required to safely perform allogeneic transplants.
“Cancer treatment can be a difficult process,” said Tom Carleton, Executive Director, Leukemia and Lymphoma Society. “You’re exhausted. You feel sick. You hurt. And you want to be with your support team. So it’s truly a blessing for the tri-state residents to have this type of high quality treatment with these outcomes available right here locally.”
“The most recent data for overall survival released by the Center for International Blood and Marrow Transplant Research (CIBMTR) demonstrates the commitment of The Jewish Hospital Blood Cancer Center to achieve the best outcomes in the region for adult blood and marrow transplant patients. We attribute this achievement to our patient-centered philosophy of care and will continue to strive for the best overall blood and marrow transplant outcomes in the future,” said Pat Davis-Hagens, Mercy Health Central Market President and CEO.
The reports show patient survival and transplant data of bone marrow in the transplant outcomes registry of the C.W. Bill Young Cell Transplantation Program, also called the Stem Cell Therapeutic Outcomes Database. Information in the transplant outcomes registry is used to guide clinical decisions and identify ways to improve transplant outcomes using research from the CIBMTR. The transplant outcomes registry is managed under a federal contract by the CIBMTR. For more information on transplant data, click here.Comments (5)